CoChat

Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

Background The effect of systemic iron overload on outcomes after allogeneic haemopoietic cell transplantation (HCT) has been a matter of substantial debate. We aimed to investigate the predictive value of both stored (MRI-derived liver iron content) and biologically active iron (enhanced labile plasma iron; eLPI) on post-transplantation outcomes in patients with acute myeloid leukaemia or myelodysplastic syndrome undergoing allogenic HCT. Methods The prospective, multicentre, observational, ALLogeneic Iron inVEstigators (ALLIVE) trial recruited patients at five centres in Germany. We enrolled patients with acute myeloid leukaemia or myelodysplastic syndrome undergoing allogeneic HCT. Patients underwent cytotoxic conditioning for a median of 6 days (IQR 6-7) before undergoing allogeneic HCT and were followed up for up to 1 year (±3 months) post-transplantation. eLPI was measured in serum samples with the FeROS eLPI kit (Aferrix, Tel-Aviv, Israel) and values greater than 0·4 μmol/L were considered to represent raised eLPI. Liver iron content was measured by MRI. The primary endpoints were the quantitative delineation of eLPI dynamics during allogeneic HCT and the correlation coefficient between liver iron content before HCT and dynamic eLPI (eLPI dyn ; maximum eLPI minus baseline eLPI). All patients with available data were included in all analyses. This is the final analysis of this completed trial, which is registered with ClinicalTrials.gov, number NCT01746147. Findings Bet…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2352-3026(18)30036-x

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 34 references

Cited by

See all 60

Metadata

Authors
Wermke, M., Eckoldt, J., Götze, K. S., Klein, S. A., Bug, G., de Wreede, L. C., Kramer, M., Stölzel, F., von Bonin, M., Schetelig, J., Laniado, M., Plodeck, V., Hofmann, W.-K., Ehninger, G., Bornhäuser, M., Wolf, D., Theurl, I., & Platzbecker, U.
Affiliations
  • University Hospital Carl Gustav Carus (DE)
  • Deutsches Konsortium für Translationale Krebsforschung (DE)
  • University Medical Centre Mannheim (DE)
  • University Hospital Frankfurt (DE)
  • Innsbruck Medical University (AT)
Corresponding author
Wermke, Martin
Venue
The Lancet Haematology
Publisher
Elsevier BV
Published
2018-05
Volume
5
Issue
5
Pages
e201-e210
ISSN
2352-3026 (ISSN-L)
OpenAlex
W2796455901
Cited by
59
References
34
Citations by year
2026: 3 · 2025: 6 · 2024: 8 · 2023: 6 · 2022: 6 · 2021: 8 · 2020: 9 · 2019: 7 · 2018: 6
FWCI
5.38
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Haematology (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • mediaTUM (Technical University of Munich) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Health Sciences › Medicine › Hematology › Blood transfusion and management
Keywords
iron overload, acute myeloid leukemia, myelodysplastic syndrome, liver iron concentration, magnetic resonance imaging, non-relapse mortality, graft-versus-host disease, post-transplant infection, conditioning regimen, prognostic factors
MeSH terms
Aged, Female, Humans, Iron, Liver, Male, Middle Aged, Myelodysplastic Syndromes, Prospective Studies, Transplantation, Homologous, Leukemia, Myeloid, Acute, Treatment Outcome, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning, Iron Overload

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. https://app.cochat.ai/papers/10.1016/s2352-3026(18)30036-x
The paper
Wermke, M., Eckoldt, J., Götze, K. S., Klein, S. A., Bug, G., de Wreede, L. C., Kramer, M., Stölzel, F., von Bonin, M., Schetelig, J., Laniado, M., Plodeck, V., Hofmann, W.-K., Ehninger, G., Bornhäuser, M., Wolf, D., Theurl, I., & Platzbecker, U. (2018). Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(18)30036-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.